People have experienced vision improvements with BEOVU

People have
experienced
vision improvements

BEOVU was assessed in 368 people with diabetic macular edema (DME) across 2 clinical studies. Both studies measured the mean change in best corrected visual acuity (ability to read letters on an eye chart) at Year 1.

On average, people gained over 9 letters on an eye chart in each study. Some people achieved greater results. More than 1 out of 3 people in each trial gained 15 letters or more On average, people gained over 9 letters on an eye chart in each study. Some people achieved greater results. More than 1 out of 3 people in each trial gained 15 letters or more

With BEOVU, it's possible to maintain vision

Both studies also measured the percentage of people who maintained vision at Year 1.

Over 98% of people in both studies maintained their vision with BEOVU at Year 1 Over 98% of people in both studies maintained their vision with BEOVU at Year 1

Remember, staying consistent with your appointments can help maintain your vision.

Treatment every 3 months is possible with BEOVU

For the first 5 treatments, BEOVU is given every 6 weeks.* (The recommended starting dose for other anti-VEGFs is every 4 weeks according to their approved dose for DME.) BEOVU is then given once every 2 or 3 months depending on how well your eye responds to treatment.

In the clinical trials, 50% of people received BEOVU every 3 months by the end of the year In the clinical trials, 50% of people received BEOVU every 3 months by the end of the year

Talk to your doctor about what treatment schedule is best for you.

*The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every 6 weeks (approximately every 39-45 days) for the first 5 doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.

How BEOVU works

What is VEGF?

VEGF is a protein responsible for producing new blood vessels. DME can cause VEGF to become overactive, which drives the growth of new blood vessels that can leak fluid into the macula.

Diagram of DME treated with BEOVU Diagram of DME treated with BEOVU

Download our patient brochure for more guidance on DME, including how to start the conversation with your doctor.

Text
size

Contrast

Back to Top Back to Top

INDICATIONS

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

COLLAPSE

EXPAND

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

You should not use BEOVU if you have an infection in or around the eye, eye inflammation, or if you are allergic to brolucizumab or any of the ingredients in BEOVU.

BEOVU is a prescription medicine given by injection into the eye. Injections in the eye, including BEOVU, may cause an infection of the eye or retinal detachment (separation of retina from the back of the eye). It is important to contact your doctor right away if your eye becomes red, sensitive to light, painful, or you develop any change in your vision.

Increased eye pressure has been seen within 30 minutes of an eye injection, including BEOVU. Sustained increases in eye pressure also have been reported. Your doctor should monitor for this when you receive a BEOVU injection.

There is a potential risk of stroke, heart attack, or blood clots in patients receiving eye injections of vascular endothelial growth factor (VEGF) inhibitor drugs, including BEOVU. Sudden vision loss due to blockage of the blood vessels in the back of the eye and inflammation of blood vessels in the back of the eye have been reported.

The most common side effects reported in patients receiving BEOVU in the wet AMD studies were reduced clarity in vision, cataract, broken blood vessels in the eye, eye pain, and vitreous floaters (moving spots in the field of vision). The most common side effect reported in patients receiving BEOVU in the DME studies was broken blood vessels in the eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

Please see full Prescribing Information.

INDICATIONS

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).